ATRC News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

AT

Mkt Cap

$2.85B

Volume

480.86K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and MedtronicThe global atrial fibrillation treatment devices market is expected to grow at a 13.1% CAGR from $9.6 billion in 2026 to $29 billion by 2035, driven by aging populations, rising AF prevalence affecting 50-60 million people worldwide, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Pulsed field ablation is forecast to generate over 60% of market revenue by 2035, while North America will retain approximately 50% of global market share. Asia-Pacific is expected to register the fastest regional growth.GlobeNewswire Inc. · Aug 26, 2026

Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for InvestorsAtriCure director Maggie Yuen sold 3,500 shares (20% of her stake) at $38.42 per share on August 5, 2026, totaling $134,470. The sale occurred after the company reported strong Q2 results with 13% revenue growth to $154 million and expanded gross margins to 77%. The stock has surged over 60% since June lows, and analysts suggest the director sales likely reflect a post-earnings trading window opening rather than loss of confidence in the company.The Motley Fool · Aug 7, 2026

Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares valued at $377,000, representing a significant portion of his holdings. Despite the sale, the company shows potential with 16% year-over-year sales growth and improving financial metrics.The Motley Fool · Nov 29, 2025

Questex’s Fierce Healthcare Announces 2025 Fierce DEI Award FinalistsQuestex's Fierce Healthcare announces the finalists of the second annual Fierce DEI Awards, which celebrate outstanding achievements in Diversity, Equity, and Inclusion within the healthcare industry. The finalists include organizations, initiatives, and individuals recognized for their contributions to creating a more equitable and inclusive healthcare environment.GlobeNewswire Inc. · May 14, 2025

AtriCure gains China's nod for heart surgery device - Investing.comAtriCure, a medical device company, has received approval from China's National Medical Products Administration to market its AtriClip Left Atrial Appendage Exclusion System in China. This is a key development in the company's global expansion strategy, as China represents a significant market opportunity.Investing.com · Jul 23, 2024

Cracking The Code: Understanding Analyst Reviews For AtriCureIn the latest quarter, 6 analysts provided ratings for AtriCure (NASDAQ:ATRC), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $44.0, along with a high estimate of $58.00 and a low estimate of $32.00. A 10.66% drop is evident in the current average compared to the previous average price target of $49.25. Deciphering Analyst Ratings: An In-Depth Analysis A comprehensive examination of how financial experts perceive AtriCure is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Matson Needham Lowers Buy $40.00 $46.00 Suraj Kalia Oppenheimer Announces Outperform $32.00 - Mike Matson Needham Maintains Buy $46.00 - Danielle Antalffy UBS Raises Buy $58.00 $57.00 Rick Wise Stifel Lowers Buy $42.00 $50.00 Mike Matson Needham Raises Buy $46.00 $44.00 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtriCure. This information offers a snapshot of how analysts perceive the ...Full story available on Benzinga.comBenzinga · May 2, 2024

Compared to Estimates, AtriCure (ATRC) Q1 Earnings: A Look at Key MetricsThe headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.Zacks Investment Research · May 2, 2024

AtriCure (ATRC) Reports Q1 Loss, Tops Revenue EstimatesAtriCure (ATRC) delivered earnings and revenue surprises of -19.05% and 2.19%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 1, 2024

AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain ManagementAtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.Zacks Investment Research · Apr 19, 2024

Key Takeaways From AtriCure Analyst RatingsIn the preceding three months, 4 analysts have released ratings for AtriCure (NASDAQ:ATRC), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for AtriCure, presenting an average target of $48.0, a high estimate of $58.00, and a low estimate of $42.00. This current average represents a 4.63% decrease from the previous average price target of $50.33. Analyzing Analyst Ratings: A Detailed Breakdown An in-depth analysis of recent analyst actions unveils how financial experts perceive AtriCure. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Matson Needham Maintains Buy $46.00 - Danielle Antalffy UBS Raises Buy $58.00 $57.00 Rick Wise Stifel Lowers Buy $42.00 $50.00 Mike Matson Needham Raises Buy $46.00 $44.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to AtriCure. This offers insight into analysts' perspectives on the current state of the company. Rating: Analysts unravel qualitative evaluations for ...Full story available on Benzinga.comBenzinga · Apr 10, 2024

AT

ATRCAtriCure, Inc.

ATRC

Pay with—

Available Balance0.00

Your PositionYou don't own any ATRC yet.

Related Tickers

Earnings